Filing Flows › Biocryst Pharmaceuticals (BCRX) › Guidance history
Biocryst Pharmaceuticals (BCRX) guidance history: what it guided and what it reported
Biocryst Pharmaceuticals gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance twice and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $635M–$660M (May 6, 2026) → raised $690M–$715M (Aug 5, 2026) → raised $715M–$730M (Nov 4, 2026) | — | to be reported | — |
The latest quarter
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Questions
Does Biocryst Pharmaceuticals beat its guidance?
Biocryst Pharmaceuticals gave guidance in 3 earnings releases on file since May 6, 2026. Its releases raised guidance twice and lowered it 0 times.
How often does Biocryst Pharmaceuticals raise guidance?
Its earnings releases raised guidance twice and lowered it 0 times since May 6, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.